Comparison of efficacy and tolerance of first-line palliative chemotherapy EOX and mDCF regimens in patients with locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma without overexpression of HER2 receptors

Preview format:

Object preview unavailable

We use files, through the cookie quality improvement layer of our website.For more information, please read the document